342 related articles for article (PubMed ID: 24433259)
1. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
Wolff JM; Abrahamsson PA; Irani J; da Silva FC
BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
[TBL] [Abstract][Full Text] [Related]
2. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
4. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
[TBL] [Abstract][Full Text] [Related]
5. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.
Salonen AJ; Taari K; Ala-Opas M; Sankila A; Viitanen J; Lundstedt S; Tammela TL;
Scand J Urol; 2014 Dec; 48(6):513-22. PubMed ID: 24679247
[TBL] [Abstract][Full Text] [Related]
7. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
8. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
[TBL] [Abstract][Full Text] [Related]
9. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
Kratiras Z; Konstantinidis C; Skriapas K
Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
[TBL] [Abstract][Full Text] [Related]
10. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
11. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
12. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
13. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
Abrahamsson PA
Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
15. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
16. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
18. Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.
Janzen BW; Ong A; Penner M; Koul R; Dubey A; Ahmed S; Bashir B; Chowdhury A; Dawe DE; Nayak J; Kim JO
Am J Clin Oncol; 2020 Dec; 43(12):865-871. PubMed ID: 32976179
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
20. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
